News & Updates

The use of bempedoic acid helps lower low-density lipoprotein cholesterol (LDL-C) levels and subsequently reduce cardiovascular events in individuals at high cardiovascular risk, according to the CLEAR* Outcomes trial.

Monthly administration of olezarsen 50 or 80 mg significantly reduced triglyceride levels in patients with predominantly moderate hypertriglyceridemia (HTG) and elevated cardiovascular (CV) risk, according to the Bridge-TIMI 73a trial presented at ACC.24.

Epilepsy surgery may hold promise for carefully selected patients past the age of 50 years, according to a study.

Patients using multiple insulin injections demonstrate no significant difference in changes to A1c, insulin requirements, or weight after a year of treatment with a sodium glucose transporter 2 (SGLT2) inhibitor or glucagon-like peptide 1 (GLP1) receptor agonist, as shown in a study.

[ Dr. Augusto Litonjua ]

Elevated nonhigh-density lipoprotein cholesterol (non–HDL-C) levels in childhood that persist into adulthood poses an increased risk of cardiovascular disease (CVD), according to a study. But the good news is that the resolution of dyslipidaemic non–HDL-C levels adulthood may help prevent CVD events.

For patients with multiple sclerosis (MS) who are receiving treatment with natalizumab, getting shots with inactivated vaccines is safe and immunogenic, with the positive results persisting regardless of the duration of natalizumab therapy, as shown in a study.